查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1726260

全球Semaglutide市場：市場規模、佔有率、趨勢分析（按產品、用途、給藥途徑、分銷管道和地區）、細分市場預測（2025-2035 年）

Semaglutide Market Size, Share & Trends Analysis Report By Product (Ozempic, Wegovy, Rybelsus), By Application (Type 2 Diabetes Mellitus, Obesity), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2035
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

Semaglutide市場成長與趨勢

根據Grand View Research, Inc.的最新報告，預計到2035年全球Semaglutide市場規模將達到936億美元，預測期內的複合年成長率為10.47%。

隨著全球糖尿病和肥胖症的盛行率不斷上升，Semaglutide產業正經歷成長。糖尿病管理中對Glucagon-Like Peptide-1受體促效劑(GLP-1 RA) 的需求不斷增加，使得Semaglutide成為重要的治療選擇。市場受到監管部門的核准、擴大的臨床適應症以及支持採用先進的糖尿病和減肥藥的醫療保健成本的增加的推動。

Semaglutide市場的主要促進因素包括第 2 型糖尿病和肥胖症的負擔日益加重，這推動了對有效治療性介入的需求。這種治療藥物在降低心血管風險和幫助控制體重方面的有效性已使其用途擴展到糖尿病治療之外。此外，優惠的報銷政策和日益普及的自我注射療法也促進了市場的成長。旨在改善藥物輸送機制的持續研究和開發活動正在進一步增強其商業性潛力。

由於對醫療保健基礎設施的投資不斷增加以及對糖尿病管理的認知不斷提高，新興經濟體的市場可能會擴大。此外，Semaglutide已被證明具有減肥功效，並已在多個地區核准，這可能會進一步滲透到肥胖症治療市場。製藥公司正在積極開發新配方，包括口服藥物和聯合治療，以提高患者的依從性並拓寬市場准入。

Semaglutide產業的特點是研發投入高、法律規範嚴格、智慧財產權保護有力。大型製藥企業主導著該行業，利用廣泛的分銷網路和夥伴關係關係來擴大其市場佔有率。競爭格局由正在進行的臨床試驗、產品生命週期管理策略以及透過配方改進和擴大適應症來實現產品差異化的努力所塑造。

Semaglutide受到多項專利保護，涵蓋其配方、製造流程和治療用途。Semaglutide的關鍵專利延長至2030年代，從而限制了學名藥的競爭並確保了主要製造商的持續市場獨佔權。投資於口服或緩釋性等替代製劑的公司正在尋求進一步的專利保護，以延長原始到期日後的商業性可用性。

最近的市場案例是Semaglutide在肥胖症治療等新治療領域核准，大大擴展了其商業性潛力。市場領導也正在建立策略聯盟和收購來增強其分銷能力。此外，臨床試驗結果證明其比現有療法具有更優異的療效，這正在加強市場採用並鼓勵對下一代製劑的進一步投資。

受糖尿病和肥胖症盛行率不斷上升、藥物輸送技術不斷進步以及持續研發舉措的推動，Semaglutide產業有望持續成長。雖然專利保護確保了近期的市場獨佔權，但替代配方或聯合治療的出現可能會改變競爭動態。產業參與企業繼續專注於擴大其適應症和地理覆蓋範圍，以適應不斷變化的市場格局。

Semaglutide市場：概述

  • 根據產品類型，Ozempic 將在 2024 年以 59.62% 的收入佔有率佔據市場主導地位，這得益於強大的臨床療效、廣泛的監管核准以及在 2 型糖尿病中的廣泛應用。
  • 根據應用，2 型糖尿病將佔據市場主導地位，2024 年的收入佔有率將達到 71.16%。
  • 根據給藥途徑，腸外給藥途徑佔據市場主導地位，到 2024 年將佔 88.46% 的佔有率。
  • 從銷售管道來看，零售藥局將引領市場，到2024年將佔55.09%的佔有率。
  • 市場的主要參與企業包括諾和諾德、禮來、Viking Therapeutics、Lexicon Pharmaceuticals、Biocon 和Astra Zeneca。Semaglutide專利到期後，隨著生物相似藥製造商進入市場，競爭預計會更加激烈。
  • 2025年3月，諾和諾德的3b期STRIDE試驗顯示，Ozempic（Semaglutide1.0毫克）使患有第2型糖尿病和周邊動脈疾病的成年患者的步行距離提高了13%。研究結果已在ACC2025上發表並發表在《刺胳針》雜誌。諾和諾德已向 EMA 和 FDA 提交了標籤延期申請。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章Semaglutide市場：促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析：按階段
    • 專利到期分析
    • 定價分析
    • 競爭格局：專利到期後的Semaglutide市場中新興的生物相似藥

第4章Semaglutide市場：按產品分類的業務分析

  • 各產品市場佔有率（2024 年及 2035 年）
  • 產品儀表板
  • 市場規模預測及產品趨勢分析（2018-2035）
  • 奧澤姆皮克
  • 韋戈維
  • 魯貝爾蘇斯
  • 其他

第5章Semaglutide市場：按應用進行的業務分析

  • 按應用分類的市場佔有率（2024 年和 2035 年）
  • 特定於應用程式的儀表板
  • 按應用分類的市場規模預測和趨勢分析（2018-2035）
  • 2型糖尿病
  • 肥胖
  • 其他

第6章Semaglutide市場：依給藥途徑進行的業務分析

  • 按管理途徑分類的市場佔有率（2024 年和 2035 年）
  • 管理路線儀表板
  • 按管理途徑分類的市場規模預測和趨勢分析（2018-2035）
  • 腸外
  • 口服

第7章Semaglutide市場：按分銷管道進行的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2035 年）
  • 分銷通路儀表板
  • 按分銷管道分類的市場規模預測和趨勢分析（2018-2035）
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第8章Semaglutide市場：按地區分類的業務分析

  • 各地區市場佔有率（2024 年及 2035 年）
  • 區域儀表板
  • 各地區市場規模預測及趨勢分析（2018-2035）
  • 北美洲
    • 按國家/地區（2018-2035 年）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 參與企業概況
  • 公司市場地位分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Novo Nordisk A/S
    • Eli Lilly
    • Viking Therapeutics
    • Lexicon Pharmaceuticals
    • Biocon
    • AstraZeneca
Product Code: GVR-4-68040-549-6

Semaglutide Market Growth & Trends:

The global semaglutide market size is anticipated to reach USD 93.60 billion by 2035, growing at a CAGR of 10.47% during the forecast period, according to a new report by Grand View Research, Inc. The semaglutide industry is experiencing growth, driven by the increasing prevalence of diabetes and obesity worldwide. The rising demand for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes management has positioned semaglutide as a key therapeutic option. The market is influenced by regulatory approvals, expansion in clinical indications, and growing healthcare expenditures that support the adoption of advanced diabetes and obesity treatments.

The primary drivers of the market for semaglutide include the increasing burden of type 2 diabetes and obesity, which have escalated the demand for effective therapeutic interventions. The drug's efficacy in reducing cardiovascular risks and aiding weight management has led to expanded usage beyond diabetes treatment. Additionally, favorable reimbursement policies and the growing adoption of self-administered injectable therapies contribute to market growth. Continuous research and development (R&D) activities aimed at improving drug delivery mechanisms further enhance its commercial potential.

The market presents opportunities for expansion in emerging economies due to rising healthcare infrastructure investments and increasing awareness of diabetes management. There is also potential for further market penetration in obesity treatment, as semaglutide has demonstrated efficacy in weight reduction, leading to regulatory approvals in multiple regions. Pharmaceutical companies are actively exploring novel formulations, including oral versions and combination therapies, to enhance patient compliance and broaden market reach.

The semaglutide industry is characterized by high R&D investment, stringent regulatory oversight, and strong intellectual property protection. Leading pharmaceutical firms dominate the landscape, leveraging extensive distribution networks and partnerships to expand their market presence. The competitive environment is shaped by ongoing clinical trials, product lifecycle management strategies, and efforts to differentiate products through formulation advancements and expanded indications.

Semaglutide is protected by multiple patents that cover its formulation, manufacturing process, and therapeutic applications. The primary patent for semaglutide extends into the 2030s, limiting generic competition and ensuring continued market exclusivity for key manufacturers. Companies investing in alternative formulations, such as oral and extended-release versions, seek additional patent protections to extend commercial viability beyond initial expiration dates.

Recent market instances include regulatory approvals for semaglutide in new therapeutic areas, such as obesity treatment, which has significantly expanded its commercial potential. Market leaders have also engaged in strategic collaborations and acquisitions to strengthen distribution capabilities. Additionally, clinical trial results demonstrating superior efficacy compared to existing therapies have reinforced market adoption and driven further investment in next-generation formulations.

The semaglutide industry is poised for sustained growth, supported by increasing diabetes and obesity prevalence, technological advancements in drug delivery, and ongoing R&D initiatives. While patent protections ensure near-term market exclusivity, competitive dynamics may shift as alternative formulations and combination therapies emerge. Industry participants continue to focus on expanding indications and geographic reach to capitalize on the evolving market landscape.

Semaglutide Market Report Highlights:

  • Based on product, Ozempic dominated the market with a revenue share of 59.62% in 2024, driven by strong clinical efficacy, broad regulatory approvals, and increasing adoption for type 2 diabetes.
  • Based on application, Type 2 Diabetes Mellitus dominated the market and accounted for a revenue share of 71.16% in 2024, driven by its rising global prevalence and increasing adoption of advanced therapies.
  • Based on route of administration, parenteral route of administration dominated the market and accounted for a share of 88.46% in 2024, driven by the widespread adoption of Ozempic and Wegovy, both available as injectable formulations.
  • Based on distribution channel, retail pharmacies led the market and accounted for a share of 55.09% in 2024, driven by increasing consumer demand for GLP-1 receptor agonists like Ozempic and Wegovy.
  • Key market players include Novo Nordisk, Eli Lilly, Viking Therapeutics, Lexicon Pharmaceuticals, Biocon, and AstraZeneca. Competition is expected to intensify as biosimilar manufacturers enter the market after semaglutide's patent expires.
  • In March 2025, Novo Nordisk's phase 3b STRIDE trial showed that Ozempic (semaglutide 1.0 mg) improved walking distance by 13% in adults with type 2 diabetes and PAD. Results were presented at ACC 2025 and published in The Lancet. Novo Nordisk has submitted a label extension application to the EMA and FDA.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Semaglutide Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis, by Phase
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis
    • 3.3.6. Competitive Landscape: Emerging Biosimilars in the Post-Patent Semaglutide Market

Chapter 4. Semaglutide Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2035
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2035 (USD Million)
  • 4.4. Ozempic
    • 4.4.1. Ozempic Market, 2018 - 2035 (USD Million)
  • 4.5. Wegovy
    • 4.5.1. Wegovy Market, 2018 - 2035 (USD Million)
  • 4.6. Rybelsus
    • 4.6.1. Rybelsus Market, 2018 - 2035 (USD Million)
  • 4.7. Others
    • 4.7.1. Other Product Market, 2018 - 2035 (USD Million)

Chapter 5. Semaglutide Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2035
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2035 (USD Million)
  • 5.4. Type 2 Diabetes Mellitus
    • 5.4.1. Type 2 Diabetes Mellitus Market, 2018 - 2035 (USD Million)
  • 5.5. Obesity
    • 5.5.1. Obesity Market, 2018 - 2035 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2035 (USD Million)

Chapter 6. Semaglutide Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2035
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2035 (USD Million)
  • 6.4. Parenteral
    • 6.4.1. Parenteral Market, 2018 - 2035 (USD Million)
  • 6.5. Oral
    • 6.5.1. Oral Market, 2018 - 2035 (USD Million)

Chapter 7. Semaglutide Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2035
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2035 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2035 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2035 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2018 - 2035 (USD Million)

Chapter 8. Semaglutide Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2035
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2035:
  • 8.4. North America
    • 8.4.1. North America Semaglutide Market Estimates And Forecasts, By Country, 2018 - 2035 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. U.S. Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Uk Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Japan Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. China Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Semaglutide Market Estimates and Forecasts, 2018 - 2035 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novo Nordisk A/S
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Eli Lilly
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Viking Therapeutics
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Lexicon Pharmaceuticals
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Biocon
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. AstraZeneca
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global semaglutide market, by region, 2018 - 2035 (USD Million)
  • Table 4. Global semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 5. Global semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 6. Global semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 7. Global semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 8. North America semaglutide market, by country, 2018 - 2035 (USD Million)
  • Table 9. North America semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 10. North America semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 11. North America semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 12. North America semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 13. U.S. semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 14. U.S. Semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 15. U.S. semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 16. U.S. semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 17. Canada semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 18. Canada semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 19. Canada semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 20. Canada semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 21. Mexico semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 22. Mexico semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 23. Mexico semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 24. Mexico semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 25. Europe semaglutide market, by country, 2018 - 2035 (USD Million)
  • Table 26. Europe semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 27. Europe semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 28. Europe semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 29. Europe semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 30. UK semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 31. UK Semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 32. UK semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 33. UK semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 34. Germany semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 35. Germany semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 36. Germany semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 37. Germany semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 38. France semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 39. France Semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 40. France semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 41. France semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 42. Italy semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 43. Italy semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 44. Italy semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 45. Italy semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 46. Spain semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 47. Spain semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 48. Spain semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 49. Spain semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 50. Norway semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 51. Norway Semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 52. Norway semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 53. Norway semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 54. Denmark semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 55. Denmark semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 56. Denmark semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 57. Denmark semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 58. Sweden semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 59. Sweden semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 60. Sweden semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 61. Sweden semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 62. Asia Pacific semaglutide market, by country, 2018 - 2035 (USD Million)
  • Table 63. Asia Pacific semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 64. Asia Pacific semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 65. Asia Pacific semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 66. Asia Pacific semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 67. Japan semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 68. Japan semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 69. Japan semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 70. Japan semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 71. China semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 72. China semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 73. China semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 74. China semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 75. India semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 76. India semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 77. India semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 78. India semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 79. Australia semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 80. Australia semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 81. Australia semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 82. Australia semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 83. South Korea semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 84. South Korea semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 85. South Korea semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 86. South Korea semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 87. Thailand semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 88. Thailand semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 89. Thailand semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 90. Thailand semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 91. Latin America semaglutide market, by country, 2018 - 2035 (USD Million)
  • Table 92. Latin America semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 93. Latin America semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 94. Latin America semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 95. Latin America semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 96. Brazil semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 97. Brazil semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 98. Brazil semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 99. Brazil semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 100. Argentina semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 101. Argentina semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 102. Argentina semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 103. Argentina semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 104. Middle East & Africa Semaglutide market, by country, 2018 - 2035 (USD Million)
  • Table 105. Middle East & Africa semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 106. Middle East & Africa semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 107. Middle East & Africa semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 108. Middle East & Africa semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 109. South Africa semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 110. South Africa semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 111. South Africa semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 112. South Africa semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 113. Saudi Arabia semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 114. Saudi Arabia semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 115. Saudi Arabia semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 116. Saudi Arabia semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 117. UAE semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 118. UAE semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 119. UAE semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 120. UAE semaglutide market, by distribution channel, 2018 - 2035 (USD Million)
  • Table 121. Kuwait semaglutide market, by product, 2018 - 2035 (USD Million)
  • Table 122. Kuwait semaglutide market, by application, 2018 - 2035 (USD Million)
  • Table 123. Kuwait semaglutide market, by route of administration, 2018 - 2035 (USD Million)
  • Table 124. Kuwait semaglutide market, by distribution channel, 2018 - 2035 (USD Million)

List of Figures

  • Fig. 1 Semaglutide market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Semaglutide market dynamics
  • Fig. 12 Semaglutide market: Porter's five forces analysis
  • Fig. 13 Semaglutide market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2035 (USD Million)
  • Fig. 15 Ozempic market, 2018 - 2035 (USD Million)
  • Fig. 16 Wegovy market, 2018 - 2035 (USD Million)
  • Fig. 17 Rybelsus market, 2018 - 2035 (USD Million)
  • Fig. 18 Others market, 2018 - 2035 (USD Million)
  • Fig. 19 Application market, 2018 - 2035 (USD Million)
  • Fig. 20 Type 2 Diabetes Mellitus market, 2018 - 2035 (USD Million)
  • Fig. 21 Obesity market, 2018 - 2035 (USD Million)
  • Fig. 22 Others market, 2018 - 2035 (USD Million)
  • Fig. 23 Route of Administration market, 2018 - 2035 (USD Million)
  • Fig. 24 Parenteral market, 2018 - 2035 (USD Million)
  • Fig. 25 Oral market, 2018 - 2035 (USD Million)
  • Fig. 26 Distribution Channel market, 2018 - 2035 (USD Million)
  • Fig. 27 Hospital Pharmacies market, 2018 - 2035 (USD Million)
  • Fig. 28 Retail Pharmacies market, 2018 - 2035 (USD Million)
  • Fig. 29 Online Pharmacies market, 2018 - 2035 (USD Million)
  • Fig. 30 Semaglutide market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 34 U.S. country dynamics
  • Fig. 35 U.S. semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 40 Europe semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 45 France country dynamics
  • Fig. 46 France semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 57 Asia Pacific semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 60 China country dynamics
  • Fig. 61 China semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 62 India country dynamics
  • Fig. 63 India semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 70 Latin America semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 75 MEA semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait semaglutide market, 2018 - 2035 (USD Million)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework